Drug Profile
Research programme: Fc receptor modulators - InKine Pharmaceuticals
Alternative Names: CBP 2011 series - InKineLatest Information Update: 20 Jul 2009
Price :
$50
*
At a glance
- Originator InKine Pharmaceutical
- Class
- Mechanism of Action Fc receptor modulators; Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune haemolytic anaemia; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 03 Oct 2005 InKine Pharmaceutical has been acquired by Salix Pharmaceuticals
- 20 May 2003 Preclinical trials in Autoimmune haemolytic anaemia in USA (unspecified route)
- 20 May 2003 Preclinical trials in Rheumatoid arthritis in USA (unspecified route)